Margaret Anne Stanley, OBE FMedSci is a British virologist and epithelial biologist. She attended the Universities of London, Bristol, and Adelaide. As of 2018, she is an Emeritus Professor of Epithelial Biology in the Department of Pathology at University of Cambridge and a Fellow of the Academy of Medical Sciences. She is also an Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists and an honorary fellow of Christ's College, Cambridge. Stanley is a research scientist in the field of virology with particular focus on the human papillomavirus (HPV). Her research work has led to new scientific findings on HPV. Additionally, she uses her expertise on HPV to serve on multiple different advisory committees and journal editorial boards. Research Stanley's main research interest is the pathogenesis of HPV and she currently leads a research group focusing on the prevention and treatment of human papillomavirus infection, which causes cervical cancer. Early in her research, she generated a non-tumorigenic human cervical keratinocyte cell line, W12, from a low-grade cervical lesion. W12 cells can harbor HPV-16 episomes, and thus allow researchers the ability to investigate the complex processes of cervical cancer development. Additionally, she helped to discover the temporal association between high-level chromosomal instability and high-risk human papillomavirus (HR-HPV) integration, a key step in cervical carcinogenesis, such that integration precedes chromosomal abnormalities. She also studies the host cell responses to infection with the human papillomavirus in individuals who are immunodeficient, most commonly HIV-positive immunosuppressant individuals. Evidence from animal models show that a CD4(+) T cell-dominated Th1 response leads to regression of anogential warts, an effective cell-mediated immune response (CMI). She states that a failure to produce this effective CMI response to the human papillomavirus facilitates viral persistence and this can lead to the progression of high-grade disease and invasive cervical cancer. Career From 2000 to 2003, she was a member of the Biotechnology and Biological Sciences Research Council (BBSRC). Since then, she has served on multiple UK Research Council committees. From 2004 to 2010, she served on the Spongiform Encephalopathies Advisory Committee (SEAC). Stanley's involvement in the SEAC was to provide independent scientific data to the UK government on transmissible spongiform encephalopathies (TSEs) and advise the government's public health, food safety, and animal health policies. In 2017, Stanley was recruited by the American Society of Clinical Oncology to be on a multidisciplinary expert panel that presented new evidence-based recommendations for the